Psychiatry AtlasMedication guide · United States

Stimulant medicine

Dextroamphetamine (Zenzedi, Dexedrine Spansule, Dexedrine)

Generic name
dextroamphetamine sulfate
Brand names
Zenzedi; Dexedrine Spansule; Dexedrine
Medication class
Stimulant medicine
Forms covered
Zenzedi immediate-release tablets; Dexedrine Spansule sustained-release capsules

Article updated: 2026-10-30 · Sources last checked: 2026-11-05

Medication Safety Alerts

FDA Boxed Warning

Zenzedi immediate-release tablets; Dexedrine Spansule sustained-release capsules.

Dextroamphetamine has a high potential for abuse, misuse and addiction. Misuse can cause overdose or death, especially at higher doses or through unapproved routes. Assess risk before treatment, monitor throughout, and use secure storage and safe disposal.

Dextroamphetamine is a stimulant used for ADHD in specified pediatric populations and for narcolepsy. Zenzedi tablets and Dexedrine Spansule capsules have different age and release instructions.

What to expect: Effects on attention or wakefulness may be noticeable on the day of treatment.

Warning signs · Medicine forms
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • ADHD — Children ages 3–16. Part of a comprehensive treatment plan.Zenzedi immediate-release tablets.
  • ADHD — Children ages 6–16. Not recommended below 6.Dexedrine Spansule sustained-release capsules.
  • Narcolepsy — Adults and selected children age 6 or older. Individualized product-specific dosing.Zenzedi immediate-release tablets; Dexedrine Spansule sustained-release capsules.

Other uses (off-label)

Off-label means a medicine is prescribed for a use, age group or form that is not included in its FDA approval.

  • Adult ADHD — Adults under clinician supervision. Outside these selected labels’ stated pediatric ADHD scope.Zenzedi immediate-release tablets; Dexedrine Spansule sustained-release capsules.

What should I expect?

Effects on attention or wakefulness may be noticeable on the day of treatment. How long they last depends on the product and the person.

Review functioning, sleep and appetite as well as symptom ratings. A dose that feels stronger is not necessarily more helpful or safer.

How do I take it safely?

Take morning and any later immediate-release doses exactly as directed, avoiding late evening. Swallow Dexedrine Spansule capsules whole; do not crush or chew. Do not apply another brand’s sprinkle instructions. Zenzedi and Spansule have different pediatric ADHD age limits.

Follow blood pressure, pulse, sleep, appetite, mood, tics and growth in children. Assessment before treatment includes cardiac and family history. Dose conversions to mixed amphetamine salts or other stimulants require the prescriber.

Do not combine with an MAOI or use within 14 days after stopping one. Check medicines affecting serotonin, acidity or drug breakdown and discuss pregnancy or breastfeeding. Store securely and never share or use an unapproved route.

Do not double a missed dose or make up for it late in the day without advice. Plan stopping with the prescriber; fatigue, depression and sleep changes can follow abrupt reduction after prolonged use.

Do not use this product after a known allergy to its active medicine or ingredients; tell the pharmacist about previous medication reactions.

What side effects should I know about?

  • Reduced appetite, insomnia, abdominal discomfort, headache or nervousness.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • The boxed warning covers abuse, misuse and addiction; misuse can cause overdose or death.
  • Chest pain, fainting, a seizure, severe agitation or suspected overdose requires emergency assessment. Fever with confusion, diarrhea, tremor or rigid muscles can be serotonin syndrome; obtain urgent assessment, or emergency care for severe symptoms.
  • Report new hallucinations, mania, worsening tics or painful, cold or discolored fingers or toes promptly. Serious heart disease and changes in blood pressure, pulse or childhood growth require attention.
  • Dexedrine Spansule is not approved or recommended for ADHD below age 6. Younger children have higher drug exposure and more side effects, including weight loss, with extended-release stimulants. Report weight loss or slowed growth to the prescriber; any change needs a clinician’s plan. Immediate-release age instructions do not apply to this form.

What else should I know to stay safe?

  • Do not use with an MAOI or within 14 days after stopping one, or after product allergy. Serious heart disease and interacting medicines affecting serotonin, acidity or drug breakdown require assessment.
  • Monitor blood pressure, pulse, sleep, appetite, mood, tics and childhood growth. Pediatric ADHD age limits differ between Zenzedi and Spansule. Discuss pregnancy and breastfeeding.
  • Store securely and never share. Different stimulant products are not automatically dose-equivalent. Plan stopping after prolonged use with the prescriber because abrupt reduction can cause marked fatigue, depression and sleep changes.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • A sustained-release capsule is a distinct delivery system. Do not open it onto food merely because another stimulant brand allows that method.
  • A treatment plan should define useful attention or wakefulness and an acceptable sleep pattern; both matter when judging benefit.

How does it work?

Dextroamphetamine changes the handling of dopamine and norepinephrine, chemical messengers used by nerve cells. It increases their release and reduces their return into cells, changing communication in systems involved in attention and alertness. These actions are understood more clearly than the full pathway through which attention-deficit/hyperactivity disorder (ADHD) symptoms improve.

Explore medication science

How was this medicine developed?

The reviewed Dexedrine Spansule application was approved in 1976. Its sustained-release capsule and Zenzedi immediate-release tablets contain the same active medicine, but have different release instructions and pediatric ADHD age boundaries.

How do I say the name?

Dextroamphetamine: dex-troe-am-FET-a-meen. Capital letters show the stressed syllable.

Medicine forms and official information

Match the full name, release type and route on your prescription. Different formulations need their own prescribing instructions; do not switch or substitute them yourself.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Zenzedi (dextroamphetamine) tablets: prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Description; Clinical Pharmacology; Pharmacokinetics..

  2. Dextroamphetamine: FDA approval history
  3. Dextroamphetamine: patient medicine information
  4. Dexedrine Spansule (dextroamphetamine sulfate) sustained-release capsules: prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Description; Clinical Pharmacology/Pharmacokinetics..

  5. FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD
  6. Dexedrine Spansule FDA prescribing information
  7. Dextroamphetamine: Package Insert / Prescribing Information
  8. DailyMed - DEXTROAMPHETAMINE SULFATE tablet
  9. Mixed amphetamine salts / Adderall XR: prescribing information
  10. Dextroamphetamine: verified neutral parent, PubChem CID 5826
  11. Adderall label: amphetamine class pharmacology — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: Clinical Pharmacology: Pharmacodynamics..

  12. Frequently Asked Questions about Labeling for Prescription Medicines | FDA
  13. Serotonin syndrome: MedlinePlus Medical Encyclopedia
  14. Monitoring a person during and after antidepressant switching – NHS SPS - Specialist Pharmacy Service – The first stop for professional medicines advice
  15. Schizophrenia
  16. NIMH: Understanding psychosis

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top